Extended indication Extension of indication to include treatment of coronavirus disease 2019 (Covid 19) in hospitalised
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Baricitinib
Domain Infectious diseases
Reason of inclusion Indication extension
Main indication Other viral infections
Extended indication Extension of indication to include treatment of coronavirus disease 2019 (Covid 19) in hospitalised adult and paediatric patients aged 10 years and older who require low-flow oxygen or non invasive ventilation/high flow oxygen for Olumiant.
Proprietary name Olumiant
Manufacturer Eli Lilly
Mechanism of action JAK tyrosine kinase inhibitor
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
ATMP No
Submission date April 2021
Expected Registration May 2022
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.